Search research articles
Contact Us
Filters
Showing results (51-60 of 94) with videos related to
Page
of 10
Sort By:
Leukemia & Lymphoma
|
March 2, 2019
Modulation of immune checkpoint molecule expression in mantle cell lymphoma
Bonnie K Harrington, Esther Wheeler, Kasey Hornbuckle, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 20, 2015
Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia
James S Blachly, Amy S Ruppert, Weiqiang Zhao, et al.
Leukemia Research
|
August 2, 2014
A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia
Kami Maddocks, Amy S Ruppert, Rebekah Browning, et al.
Cancer Research
|
March 7, 2014
Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia
Warren Fiskus, Nakhle Saba, Min Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2009
Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia
Tait D Shanafelt, Neil E Kay, Kari G Rabe, et al.
Leukemia Research
|
July 23, 2013
Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia
Deborah M Stephens, Amy S Ruppert, Kami Maddocks, et al.
The Lancet. Oncology
|
June 9, 2020
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
Gilles Salles, Johannes Duell, Eva González Barca, et al.
European Journal of Haematology
|
December 9, 2025
A Phase I Study of Combination Duvelisib and Nivolumab in Patients With Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, and Richter Transformation
Aseel Alsouqi, Ying Huang, Beth Christian, et al.
British Journal of Haematology
|
April 8, 2015
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma
Beth A Christian, Ming Poi, Jeffrey A Jones, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
February 4, 2026
Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexate
Zachary J Arnold, Jordan Lundberg, Tracy Wiczer, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 94) with videos related to
Sort By:
Page
of 10
Leukemia & Lymphoma
|
March 2, 2019
Modulation of immune checkpoint molecule expression in mantle cell lymphoma
Bonnie K Harrington, Esther Wheeler, Kasey Hornbuckle, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 20, 2015
Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia
James S Blachly, Amy S Ruppert, Weiqiang Zhao, et al.
Leukemia Research
|
August 2, 2014
A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia
Kami Maddocks, Amy S Ruppert, Rebekah Browning, et al.
Cancer Research
|
March 7, 2014
Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia
Warren Fiskus, Nakhle Saba, Min Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2009
Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia
Tait D Shanafelt, Neil E Kay, Kari G Rabe, et al.
Leukemia Research
|
July 23, 2013
Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia
Deborah M Stephens, Amy S Ruppert, Kami Maddocks, et al.
The Lancet. Oncology
|
June 9, 2020
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
Gilles Salles, Johannes Duell, Eva González Barca, et al.
European Journal of Haematology
|
December 9, 2025
A Phase I Study of Combination Duvelisib and Nivolumab in Patients With Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, and Richter Transformation
Aseel Alsouqi, Ying Huang, Beth Christian, et al.
British Journal of Haematology
|
April 8, 2015
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma
Beth A Christian, Ming Poi, Jeffrey A Jones, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
February 4, 2026
Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexate
Zachary J Arnold, Jordan Lundberg, Tracy Wiczer, et al.
Page
of 10